Role of SHP2 phosphatase in KIT-induced transformation: Identification of SHP2 as a druggable target in diseases involving oncogenic KIT

Raghuveer Singh Mali, Peilin Ma, Li Fan Zeng, Holly Martin, Baskar Ramdas, Yantao He, Emily Sims, Sarah Nabinger, Joydeep Ghosh, Namit Sharma, Veerendra Munugalavadla, Anindya Chatterjee, Shuo Li, George Sandusky, Andrew W. Craig, Kevin D. Bunting, Gen Sheng Feng, Rebecca Chan, Zhong-Yin Zhang, Reuben Kapur

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Intracellular mechanism(s) that contribute to promiscuous signaling via oncogenic KIT in systemic mastocytosis and acute myelogenous leukemia are poorly understood.We show that SHP2 phosphatase is essential for oncogenic KIT-induced growth and survival in vitro and myeloproliferative disease (MPD) in vivo. Genetic disruption of SHP2 or treatment of oncogene-bearing cells with a novel SHP2 inhibitor alone or in combination with the PI3K inhibitor corrects MPD by disrupting a protein complex involving p85α, SHP2, and Gab2. Importantly, a single tyrosine at position 719 in oncogenic KIT is sufficient to develop MPD by recruiting p85α, SHP2, and Gab2 complex to oncogenic KIT. Our results demonstrate that SHP2 phosphatase is a druggable target that cooperates with lipid kinases in inducing MPD.

Original languageEnglish
Pages (from-to)2669-2678
Number of pages10
JournalBlood
Volume120
Issue number13
DOIs
StatePublished - Sep 27 2012

Fingerprint

Non-Receptor Type 11 Protein Tyrosine Phosphatase
Bearings (structural)
Systemic Mastocytosis
Phosphatidylinositol 3-Kinases
Oncogenes
Acute Myeloid Leukemia
Tyrosine
Phosphotransferases
Cells
Lipids
Growth
Proteins

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Role of SHP2 phosphatase in KIT-induced transformation : Identification of SHP2 as a druggable target in diseases involving oncogenic KIT. / Mali, Raghuveer Singh; Ma, Peilin; Zeng, Li Fan; Martin, Holly; Ramdas, Baskar; He, Yantao; Sims, Emily; Nabinger, Sarah; Ghosh, Joydeep; Sharma, Namit; Munugalavadla, Veerendra; Chatterjee, Anindya; Li, Shuo; Sandusky, George; Craig, Andrew W.; Bunting, Kevin D.; Feng, Gen Sheng; Chan, Rebecca; Zhang, Zhong-Yin; Kapur, Reuben.

In: Blood, Vol. 120, No. 13, 27.09.2012, p. 2669-2678.

Research output: Contribution to journalArticle

Mali, RS, Ma, P, Zeng, LF, Martin, H, Ramdas, B, He, Y, Sims, E, Nabinger, S, Ghosh, J, Sharma, N, Munugalavadla, V, Chatterjee, A, Li, S, Sandusky, G, Craig, AW, Bunting, KD, Feng, GS, Chan, R, Zhang, Z-Y & Kapur, R 2012, 'Role of SHP2 phosphatase in KIT-induced transformation: Identification of SHP2 as a druggable target in diseases involving oncogenic KIT', Blood, vol. 120, no. 13, pp. 2669-2678. https://doi.org/10.1182/blood-2011-08-375873
Mali, Raghuveer Singh ; Ma, Peilin ; Zeng, Li Fan ; Martin, Holly ; Ramdas, Baskar ; He, Yantao ; Sims, Emily ; Nabinger, Sarah ; Ghosh, Joydeep ; Sharma, Namit ; Munugalavadla, Veerendra ; Chatterjee, Anindya ; Li, Shuo ; Sandusky, George ; Craig, Andrew W. ; Bunting, Kevin D. ; Feng, Gen Sheng ; Chan, Rebecca ; Zhang, Zhong-Yin ; Kapur, Reuben. / Role of SHP2 phosphatase in KIT-induced transformation : Identification of SHP2 as a druggable target in diseases involving oncogenic KIT. In: Blood. 2012 ; Vol. 120, No. 13. pp. 2669-2678.
@article{f013cf0c1ffb4b36a4e448945d1e34f0,
title = "Role of SHP2 phosphatase in KIT-induced transformation: Identification of SHP2 as a druggable target in diseases involving oncogenic KIT",
abstract = "Intracellular mechanism(s) that contribute to promiscuous signaling via oncogenic KIT in systemic mastocytosis and acute myelogenous leukemia are poorly understood.We show that SHP2 phosphatase is essential for oncogenic KIT-induced growth and survival in vitro and myeloproliferative disease (MPD) in vivo. Genetic disruption of SHP2 or treatment of oncogene-bearing cells with a novel SHP2 inhibitor alone or in combination with the PI3K inhibitor corrects MPD by disrupting a protein complex involving p85α, SHP2, and Gab2. Importantly, a single tyrosine at position 719 in oncogenic KIT is sufficient to develop MPD by recruiting p85α, SHP2, and Gab2 complex to oncogenic KIT. Our results demonstrate that SHP2 phosphatase is a druggable target that cooperates with lipid kinases in inducing MPD.",
author = "Mali, {Raghuveer Singh} and Peilin Ma and Zeng, {Li Fan} and Holly Martin and Baskar Ramdas and Yantao He and Emily Sims and Sarah Nabinger and Joydeep Ghosh and Namit Sharma and Veerendra Munugalavadla and Anindya Chatterjee and Shuo Li and George Sandusky and Craig, {Andrew W.} and Bunting, {Kevin D.} and Feng, {Gen Sheng} and Rebecca Chan and Zhong-Yin Zhang and Reuben Kapur",
year = "2012",
month = "9",
day = "27",
doi = "10.1182/blood-2011-08-375873",
language = "English",
volume = "120",
pages = "2669--2678",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "13",

}

TY - JOUR

T1 - Role of SHP2 phosphatase in KIT-induced transformation

T2 - Identification of SHP2 as a druggable target in diseases involving oncogenic KIT

AU - Mali, Raghuveer Singh

AU - Ma, Peilin

AU - Zeng, Li Fan

AU - Martin, Holly

AU - Ramdas, Baskar

AU - He, Yantao

AU - Sims, Emily

AU - Nabinger, Sarah

AU - Ghosh, Joydeep

AU - Sharma, Namit

AU - Munugalavadla, Veerendra

AU - Chatterjee, Anindya

AU - Li, Shuo

AU - Sandusky, George

AU - Craig, Andrew W.

AU - Bunting, Kevin D.

AU - Feng, Gen Sheng

AU - Chan, Rebecca

AU - Zhang, Zhong-Yin

AU - Kapur, Reuben

PY - 2012/9/27

Y1 - 2012/9/27

N2 - Intracellular mechanism(s) that contribute to promiscuous signaling via oncogenic KIT in systemic mastocytosis and acute myelogenous leukemia are poorly understood.We show that SHP2 phosphatase is essential for oncogenic KIT-induced growth and survival in vitro and myeloproliferative disease (MPD) in vivo. Genetic disruption of SHP2 or treatment of oncogene-bearing cells with a novel SHP2 inhibitor alone or in combination with the PI3K inhibitor corrects MPD by disrupting a protein complex involving p85α, SHP2, and Gab2. Importantly, a single tyrosine at position 719 in oncogenic KIT is sufficient to develop MPD by recruiting p85α, SHP2, and Gab2 complex to oncogenic KIT. Our results demonstrate that SHP2 phosphatase is a druggable target that cooperates with lipid kinases in inducing MPD.

AB - Intracellular mechanism(s) that contribute to promiscuous signaling via oncogenic KIT in systemic mastocytosis and acute myelogenous leukemia are poorly understood.We show that SHP2 phosphatase is essential for oncogenic KIT-induced growth and survival in vitro and myeloproliferative disease (MPD) in vivo. Genetic disruption of SHP2 or treatment of oncogene-bearing cells with a novel SHP2 inhibitor alone or in combination with the PI3K inhibitor corrects MPD by disrupting a protein complex involving p85α, SHP2, and Gab2. Importantly, a single tyrosine at position 719 in oncogenic KIT is sufficient to develop MPD by recruiting p85α, SHP2, and Gab2 complex to oncogenic KIT. Our results demonstrate that SHP2 phosphatase is a druggable target that cooperates with lipid kinases in inducing MPD.

UR - http://www.scopus.com/inward/record.url?scp=84866866031&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866866031&partnerID=8YFLogxK

U2 - 10.1182/blood-2011-08-375873

DO - 10.1182/blood-2011-08-375873

M3 - Article

C2 - 22806893

AN - SCOPUS:84866866031

VL - 120

SP - 2669

EP - 2678

JO - Blood

JF - Blood

SN - 0006-4971

IS - 13

ER -